Company Performance - Techne reported quarterly earnings of $0.56 per share, exceeding the Zacks Consensus Estimate of $0.51 per share, and up from $0.48 per share a year ago, representing an earnings surprise of 9.80% [1] - The company posted revenues of $316.18 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.30%, and an increase from $303.43 million year-over-year [2] - Over the last four quarters, Techne has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Stock Outlook - Techne shares have declined approximately 33.8% since the beginning of the year, compared to a decline of 4.7% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $0.54 on revenues of $325.78 million, and for the current fiscal year, it is $1.89 on revenues of $1.22 billion [7] - The estimate revisions trend for Techne is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Techne belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Techne's stock performance [5]

Core Insights - Alkermes reported quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.28 per share, and down from $0.44 per share a year ago, representing an earnings surprise of -53.57% [1] - The company posted revenues of $306.51 million for the quarter, missing the Zacks Consensus Estimate by 3.22%, and down from $350.37 million year-over-year [2] - Alkermes has surpassed consensus EPS estimates only once in the last four quarters, while it has topped revenue estimates two times in the same period [2] Earnings Outlook - The sustainability of Alkermes' stock price movement will depend on management's commentary during the earnings call and future earnings expectations [3] - The current consensus EPS estimate for the upcoming quarter is $0.46 on revenues of $346.92 million, and for the current fiscal year, it is $1.76 on revenues of $1.39 billion [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Alkermes belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Alkermes' stock performance [5]